Suppression of growth in vitro and tumorigenicity in vivo of human carcinoma cell lines by transfected p16INK4

Molecular Carcinogenesis

Volumn 16, Issue 1, 1996, Pages 53-60

  Spillare, Elisa A ^a   Okamoto, Aikou ^a   Hagiwara, Koichi ^a   Demetrick, Douglas J ^b   Serrano, Manuel ^b   Beach, David ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

CDKN2; Cyclin dependent kinase inhibitor; MTS 1; Tumor suppression

Indexed keywords

ARTICLE; CARCINOGENICITY; CARCINOMA; CDKN2 GENE; CONTROLLED STUDY; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; CARRIER PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA PRIMERS; GENES, TUMOR SUPPRESSOR; HUMANS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0029891257     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199605)16:1<53::AID-MC7>3.0.CO;2-P     Document Type: Article

References (49)

1. Weinberg RA. The retinoblastoma protein and cell cycle control Cell 81:323-330, 1995.
2. Peter M, Herskowitz I. Joining the complex: Cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79:181-184, 1994.
3. Pines J. Protein kinases and cell cycle control. Semin Cell Biol 5:399-408, 1994.
4. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 266:1821-1828, 1994.
5. Grana X, Reddy EP. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211-219, 1995.
6. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7:331-342, 1993.
7. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497, 1993.
8. Harlow E. Retinoblastoma. For our eyes only. Nature 359:270-271, 1992.
9. Hollingsworth RE Jr, Chen PL, Lee WH. Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein. Curr Opin Cell Biol 5:194-200, 1993.
10. Sherr CJ. The ins and outs of RB: Coupling gene expression to the cell cycle dock. Trends Cell Biol 4:15-18, 1994.
11. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cellcycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993.
12. Sherr CJ, Roberts JM Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995.
13. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994.
14. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994.
15. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of genes regulating the cell cycle G1 check-point in human cancer. Proc Natl Acad Sci USA 91:11045-11049, 1994.
16. Mori T, Miura K, Aoki T, Nishihira T, Mon S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397, 1994.
17. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16(MST1) gene in pancreatic adenocarcinoma. Nat Genet 8:27-32, 1994.
18. Jen J, Harper JW, Bigner SH, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353-6358, 1994.
19. Spruck CH, Gonzalez-Zulueta M, Shlbata A, et al. p16 Gene in uncultured tumours. Nature 370:183-184, 1994.
20. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-417, 1994.
21. Zhang SY, Klein-Szanto AJ, Sauter ER, et al. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053, 1994.
22. Xu L, Sgroi D, Sterner CJ, et al. Mutational analysis of CDKN2 (MTS1/p16mk4) in human breast carcinomas. Cancer Res 54:5262-5264, 1994.
23. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547-5551, 1994.
24. Komiya A, Suzuki H, Aida S, Yatani R, Shimazaki J. Mutational analysis of CDKN2 (CDK41/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86:622-625, 1995.
25. Brenner AJ, Aldaz CM. Chromosome 9p allelic loss and p16/ CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells. Cancer Res 55:2892-2895, 1995.
26. lgaki H, Sasaki H, Tachimori Y, et al. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res 55:3421-3423, 1995.
27. Dreyling MH, Bohlander SK, Adeyanju MO, Olopade OL Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 55:984-988, 1995.
28. Otsuki T, Clark HM, Wellmann A, Jaffe ES, Raffeld M. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436-1440, 1995.
29. Gomi A, Sakai R, Ogawa S, Shinoda S, Hirai H, Masuzawa T. Frequent loss of the cyclin-dependent kinase-4 inhibitor gene in human gliomas. Jpn J Cancer Res 86:342-364, 1995.
30. Nishikawa R, Furnari FB, Lin H, et al. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res 55:1941-1945, 1995.
31. Okamoto A, Hussain SP, Hagiwara K, et al. Mutations in the P16INK4/MTS1/CDKN2, p15INK4B/MTS2 and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448-1451, 1995.
32. Reed JA, Loganzo F, Jr, Shea CR, et al. Loss of expression of the p16/cydin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55:2713-2718, 1995.
33. Walker DG, Duan W, Popovic EA, Kaye AH, Tomlinson FH, Lavin M. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55:20-23, 1995.
34. Xiao S, Li D, Corson JM, Vijg J, Fletcher JA. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 55:2968-2971, 1995.
35. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.
36. Liu L, Lassam NJ, Slingerland JM, et al. Germline p16INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11:405-412, 1995.
37. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Bar-Sagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 267:249-252, 1995.
38. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HJ. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55:1351-1354, 1995.
39. Jin X, Nguyen D, Zhang W-W, Kyritsis AP, Roth JA. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res 55:3250-3253, 1995.
40. Shapiro GI, Edwards CD, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995.
41. Aagaard L, Lukas J, Bartkova J, Kjerulff AA, Strauss M, Bartek J. Aberrations of p16Ink4 and retmoblastoma tumour-suppressor genes occur in distinct sub-sets of human cancer cell lines, Int J Cancer 61:115-120, 1995.
42. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma protein-dependent cell-cycle inhibition by the tumour suppressor p 16. Nature 375:503-506, 1995.
43. Koh J, Enders GH, Oynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375:506-510, 1995.
44. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 92:6289-6293, 1995.
45. Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939-2952, 1994.
46. Wolfel T, Hauer M, Schneider J, et al. A p16INK4-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284, 1995.
47. Banks-Schlegel SP, Quintero J. Growth and differentiation of human esophageal carcinoma cell lines. Cancer Res 46:250-258, 1986.
48. Puisieux A, Galvin K, Troalen F, et al. Retinoblastoma and p53 tumor suppressor genes in human nepatoma cell lines, FASEB J 7:1407-1413, 1993.
49. Shew JY, Lin BT, Chen PL, Tseng BY, Yang-Feng TL, Lee WH. C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. Proc Natl Acad Sci USA 87:6-10, 1990.